These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 35867199)

  • 41. Imeglimin: A Clinical Pharmacology Review.
    Chevalier C; Fouqueray P; Bolze S
    Clin Pharmacokinet; 2023 Oct; 62(10):1393-1411. PubMed ID: 37713097
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetics of Single Doses of BI 425809 in Healthy Chinese and Japanese Subjects: A Randomized Study.
    Tsuda Y; Ugai H; Wunderlich G; Shin JG
    Clin Ther; 2019 May; 41(5):961-971. PubMed ID: 31005336
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Randomized, double-blind, placebo-controlled, phase I study of the safety and pharmacokinetics of namilumab in healthy Japanese and Caucasian men
.
    Tanaka S; Harada S; Hiramatsu N; Nakaya R; Kawamura M
    Int J Clin Pharmacol Ther; 2018 Nov; 56(11):507-517. PubMed ID: 30168415
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Single- and Multiple-Dose Pharmacokinetics and Safety of Vilaprisan in Healthy Postmenopausal Japanese Women: A Randomized Clinical Trial.
    Schultze-Mosgau MH; Matsuki S; Okumura K; Kaneko M
    Eur J Drug Metab Pharmacokinet; 2022 Jan; 47(1):49-56. PubMed ID: 34635989
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetics, Pharmacodynamics, and Safety of Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized, Single-blind, Placebo-controlled Trial.
    Sasaki T; Seino Y; Fukatsu A; Ubukata M; Sakai S; Samukawa Y
    Adv Ther; 2015 Apr; 32(4):319-40. PubMed ID: 25855342
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Imeglimin Hydrochloride: First Approval.
    Lamb YN
    Drugs; 2021 Sep; 81(14):1683-1690. PubMed ID: 34472031
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetics, safety, and tolerability of GLPG0259, a mitogen-activated protein kinase-activated protein kinase 5 (MAPKAPK5) inhibitor, given as single and multiple doses to healthy male subjects.
    Namour F; Vanhoutte FP; Beetens J; Blockhuys S; De Weer M; Wigerinck P
    Drugs R D; 2012 Sep; 12(3):141-63. PubMed ID: 22950522
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacokinetics, pharmacodynamics and safety of tolvaptan, a novel, oral, selective nonpeptide AVP V2-receptor antagonist: results of single- and multiple-dose studies in healthy Japanese male volunteers.
    Kim SR; Hasunuma T; Sato O; Okada T; Kondo M; Azuma J
    Cardiovasc Drugs Ther; 2011 Dec; 25 Suppl 1():S5-17. PubMed ID: 22120090
    [TBL] [Abstract][Full Text] [Related]  

  • 49. First-in-Human, Single-Ascending Dose and Food Effect Studies to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Cetagliptin, a Dipeptidyl Peptidase-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus.
    Wang L; Lu J; Zhou S; Zhao Y; Xie L; Zhou C; Chen J; Ding S; Xie D; Ding J; Yu Q; Shen H; Hao G; Shao F
    Clin Drug Investig; 2021 Nov; 41(11):999-1010. PubMed ID: 34655432
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
    Vaughan D; Speed J; Medve R; Andrews JS
    Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacokinetics and safety of Enasidenib following single oral doses in Japanese and Caucasian subjects.
    Li Y; Liu L; Gomez D; Chen J; Tong Z; Palmisano M; Zhou S
    Pharmacol Res Perspect; 2018 Dec; 6(6):e00436. PubMed ID: 30386625
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Single- and Multiple-Dose Pharmacokinetics, Safety and Tolerability of Lurasidone in Healthy Chinese Subjects.
    Hu C; Wang Y; Song R; Yu C; Luo X; Jia J
    Clin Drug Investig; 2017 Sep; 37(9):861-871. PubMed ID: 28695535
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and safety of imeglimin in type 2 diabetes: A systematic review and meta-analysis of randomized placebo-controlled trials.
    Singh AK; Singh A; Singh R; Misra A
    Diabetes Metab Syndr; 2023 Feb; 17(2):102710. PubMed ID: 36702046
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Pharmacological profile and clinical efficacy of imeglimin hydrochloride (TWYMEEG
    Nagamine J
    Nihon Yakurigaku Zasshi; 2023; 158(2):193-202. PubMed ID: 36858505
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety, Tolerability, and Pharmacokinetics of the Novel Antiviral Agent Ensitrelvir Fumaric Acid, a SARS-CoV-2 3CL Protease Inhibitor, in Healthy Adults.
    Shimizu R; Sonoyama T; Fukuhara T; Kuwata A; Matsuo Y; Kubota R
    Antimicrob Agents Chemother; 2022 Oct; 66(10):e0063222. PubMed ID: 36094202
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety, Tolerability and Pharmacokinetics of Icapamespib, a Selective Epichaperome Inhibitor, in Healthy Adults.
    Silverman MH; Duggan S; Bardelli G; Sadler B; Key C; Medlock M; Reynolds L; Wallner B
    J Prev Alzheimers Dis; 2022; 9(4):635-645. PubMed ID: 36281667
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Imeglimin increases glucose-dependent insulin secretion and improves β-cell function in patients with type 2 diabetes.
    Pacini G; Mari A; Fouqueray P; Bolze S; Roden M
    Diabetes Obes Metab; 2015 Jun; 17(6):541-545. PubMed ID: 25694060
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety, Tolerability, and Pharmacokinetics of the Novel Hepatitis B Virus Expression Inhibitor GST-HG131 in Healthy Chinese Subjects: a First-in-Human Single- and Multiple-Dose Escalation Trial.
    Li X; Liu Y; Yao H; Wang M; Gao L; Lou J; Mao J; Wu W; Zhou Y; Tang Y; Yan W; Hu Y; Ding C; Chen S; Niu J; Ding Y
    Antimicrob Agents Chemother; 2022 May; 66(5):e0009422. PubMed ID: 35404074
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety, pharmacokinetics, and pharmacodynamics of milvexian in healthy Japanese participants.
    Perera V; Wang Z; Lubin S; Ueno T; Shiozaki T; Chen W; Xu X; Seiffert D; DeSouza M; Murthy B
    Sci Rep; 2022 Mar; 12(1):5165. PubMed ID: 35338177
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase I Clinical Study of ZYAN1, A Novel Prolyl-Hydroxylase (PHD) Inhibitor to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Oral Administration in Healthy Volunteers.
    Kansagra KA; Parmar D; Jani RH; Srinivas NR; Lickliter J; Patel HV; Parikh DP; Heading H; Patel HB; Gupta RJ; Shah CY; Patel MR; Dholakia VN; Sukhadiya R; Jain MR; Parmar KV; Barot K
    Clin Pharmacokinet; 2018 Jan; 57(1):87-102. PubMed ID: 28508936
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.